Ed Silverman from STAT News - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry		STAT+: 3 issues to watch in pharma in 2024 - 5 months ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 5 months ago STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace - 5 months ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - 5 months ago STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors - 5 months ago STAT+: Pharmalittle: Illumina will divest Grail after court finds deal was anti-competitive; FDA found problems at Moderna facility - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Pharmalittle: Bluebird claims big insurer will cover its sickle cell therapy; House Republicans threaten to subpoena FDA commish - 5 months ago STAT+: In response to criticism, FDA publishes new database of wayward clinical trial sponsors - 5 months ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - 5 months ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - 5 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 5 months ago STAT+: Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns - 5 months ago STAT+: Pharmalittle: Bluebird’s sickle-cell screwups may prompt a sale; drugmakers raised prices on widely used meds without new clinical evidence - 5 months ago STAT+: The prices of 8 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2022, report finds - 5 months ago STAT+: Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year - 5 months ago STAT+: Vertex gets a win as Colorado board leaves cystic fibrosis drug off a list of unaffordable medicines - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - 5 months ago STAT+: Biden proposal targeting pharma patents spurs industry fears and consumer doubts - 5 months ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - 5 months ago STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices - 5 months ago Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents - 5 months ago STAT+: U.S. judge orders Minnesota to pause its drug pricing transparency law over constitutional issues - 5 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 5 months ago STAT+: Pharmalittle: CVS to overhaul how it’s paid for drugs; Biden drug-shortage plan won’t expand chemo supplies - 5 months ago STAT+: FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety, analysis finds - 5 months ago STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal - 6 months ago STAT+: U.S. Supreme Court to review controversial Purdue Pharma bankruptcy settlement - 6 months ago STAT+: Texas AG accuses Pfizer of ‘intentionally’ overstating Covid-19 vaccine effectiveness - 6 months ago STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders - 6 months ago STAT+: Pharmalittle: FDA probes CAR-T therapy for links to lymphoma; White House official attacks Bristol over Medicare price talks - 6 months ago STAT+: Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it’s not enough - 6 months ago STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages - 6 months ago STAT+: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs - 6 months ago STAT+: Most clinical trials run in Canada failed to take basic steps toward transparency, analysis finds - 6 months ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - 6 months ago STAT+: Sales of antibiotics for food-producing animals dropped by more than half in Europe over the past decade - 6 months ago STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs - 6 months ago STAT+: FDA’s Janet Woodcock to retire early next year - 6 months ago STAT+: FDA cites Dr. Reddy’s for quality control problems at a biologics plant - 6 months ago STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data - 6 months ago STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds - 6 months ago STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment - 6 months ago STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without - 6 months ago STAT+: Michigan bill that would pare back pharma liability shield law moves closer to enactment - 6 months ago STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago
2	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism		STAT+: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs - 6 months ago STAT+: FDA’s Janet Woodcock to retire early next year - 6 months ago